Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-28 @ 12:05 AM
Study NCT ID:
NCT00898794
Status:
UNKNOWN
Last Update Posted:
2013-08-07
First Post:
2009-05-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
Sponsor:
Kantonsspital Graubuenden
Organization:
Study Overview
Official Title:
Influence of Bevacizumab and VEGF on Platelet Aggregation
Status:
UNKNOWN
Status Verified Date:
2011-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.
PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.
PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.
Detailed Description:
OBJECTIVES:
* To determine the influence of bevacizumab on platelet aggregation in patients receiving bevacizumab for cancer.
* To determine the influence of VEGF on platelet aggregation.
* To determine the influence of VEGF or bevacizumab on cyclooxygenesis.
* To determine if the sequence of medication plays a role in platelet aggregation.
OUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).
* To determine the influence of bevacizumab on platelet aggregation in patients receiving bevacizumab for cancer.
* To determine the influence of VEGF on platelet aggregation.
* To determine the influence of VEGF or bevacizumab on cyclooxygenesis.
* To determine if the sequence of medication plays a role in platelet aggregation.
OUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| CDR0000631252 | REGISTRY | PDQ (Physician Data Query) | View |